Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab for Desensitization in Highly-HLA Sensitized Patients Awaiting Renal Transplant
NCT03380962Phase 2Completed
- Start
- Feb 2018
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in antibody mediated rejection (AMR). Started Feb 2018; status: completed.
02
Drugs
clazakizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03380962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380962.